Friday, September 29, 2017

Biotech Stocks Facing FDA Decision In October

The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.

from RTT - Biotech http://ift.tt/2yLZ3SI
via IFTTT

No comments:

Post a Comment